# A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)

> **NCT07698899** · PHASE1 · RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 24 (estimated)

## Conditions studied

- Recurrent Medulloblastoma
- Refractory Medulloblastoma
- CNS Metastases
- Central Nervous System Metastasis

## Interventions

- **BIOLOGICAL:** 25 mCi 177Lu- DTPA-omburtamab

## Key facts

- **NCT ID:** NCT07698899
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-02
- **Primary completion:** 2030-06-02
- **Final completion:** 2030-07-02
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2026-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07698899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07698899, "A Study of 177Lu-DTPA-Omburtamab in Children and Adolescents With Brain Cancer or Cancer That Has Spread to the Central Nervous System (CNS)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07698899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*